New therapeutic compounds against tuberculosis
In silico design of new therapeutic compounds targeting biosynthetic pathway of Mycolic acid in M. tuberculosis
Versandkostenfrei!
Versandfertig in 6-10 Tagen
51,99 €
inkl. MwSt.
PAYBACK Punkte
26 °P sammeln!
Tuberculosis (TB) proved to be a controllable , preventable and curable disease , but it still remains as a leading cause for mortality. Rational Drug Design (RDD) is basically a computer-aided molecular modeling, it is an iterative process, If it is based on the knowledge of three - dimensional (3-D) structure of the target proteins of interest; it is called "structure based drug design" or "target based drug design". Such knowledge allows to design molecules capable of binding the receptor so as to maximize the drug affinity and specificity towards the target. Mycolic acid biosynthesis pathw...
Tuberculosis (TB) proved to be a controllable , preventable and curable disease , but it still remains as a leading cause for mortality. Rational Drug Design (RDD) is basically a computer-aided molecular modeling, it is an iterative process, If it is based on the knowledge of three - dimensional (3-D) structure of the target proteins of interest; it is called "structure based drug design" or "target based drug design". Such knowledge allows to design molecules capable of binding the receptor so as to maximize the drug affinity and specificity towards the target. Mycolic acid biosynthesis pathway in Mycobacterium tuberculosis was considered a fatal target by designing inhibitors against the enzymes which play a vital role in this pathway.
Andere Kunden interessierten sich für
